

## Multi-Charged Ion Analysis of Intact Antibodies Using a Quadrupole Time-of-Flight Mass Spectrometer

Junna Nakazono

### User Benefits

- ◆ Analysis of intact antibodies can be performed using the LCMS-9030 capable of acquiring accurate mass.
- ◆ The ReSpect algorithm installed in LabSolutions Insight Explore™ CSD enables multi-charged ion analysis (charge deconvolution) of macromolecular compounds such as proteins.
- ◆ The reconstructed zero charge spectrum of glycoform patterns of monoclonal antibodies can be detected with this workflow.

### Introduction

In recent years, antibody drugs such as monoclonal antibodies and antibody drug conjugates have been actively researched and developed because of their high specificity for target molecules and fewer side effects. Unlike low molecular drugs, which can be mass-produced by chemical synthesis, antibody drugs are produced using animal cells. Therefore, it is difficult to prevent structural heterogeneity, and characterization is indispensable in the research and development of antibody drugs. Characterization items by mass spectrometry include molecular weight confirmation and glycosylation analysis of intact antibodies.

In this article, the analysis of trastuzumab, a monoclonal antibody drug, using the quadrupole time-of-flight mass spectrometer LCMS-9030 (Fig. 1) is introduced as an example. Multi-charged ion analysis (charge deconvolution) was performed on the obtained mass spectrum using the analysis software LabSolutions Insight Explore CSD.



Fig. 1 Exterior of LCMS-9030

### Sample Preparation

Trastuzumab purified in a protein A column was used for this analysis. After column purification, the sample was diluted with 0.1 % formic acid-water to a concentration of 0.5 µg/µL.

### Analysis of Trastuzumab

The HPLC and MS conditions are shown in Table 1. Using a diverter valve, the sample was introduced to the waste side at the measurement time of 0 to 4.9 minutes, and to the mass spectrometer at the measurement time of 5 to 15 minutes.

A mass chromatogram of trastuzumab is shown in Fig. 2. A peak was detected at a retention time of approximately 8.2 minutes.

Table 1 Analytical Conditions

#### UHPLC (Nexera™ X3 system)

Column:	Triart Bio C4 (2.1 mm I.D. x 150 mm L., S-3 µm, 300 Å, YMC)
Mobile Phase A:	0.1 % Formic acid - Water
Mobile Phase B:	0.1 % Formic acid - Acetonitrile
Gradient Program:	B Conc. 0 % (0-5 min) – 70 % (9 min) – 95 % (9.5-10.5 min) – 0 % (10.51 -15 min)
Flowrate:	0.4 mL/min
Column Temp.:	50 °C
Injection Volume:	1 µL

#### MS (LCMS-9030)

Ionization:	ESI positive
Nebulizing Gas Flow:	3.0 L/min
Drying gas Flow:	10.0 L/min
Heating gas Flow:	10.0 L/min
Interface Temp.:	300 °C
DL Temp.:	250 °C
Block Heater Temp.:	400 °C
MS Scan Range:	<i>m/z</i> 1000-4000




Fig. 2 Total Ion Current Chromatogram of Trastuzumab

### Multi-Charged Ion Analysis

Multi-charged ions are distributed in the mass spectrum of macromolecular compounds such as proteins. The ReSpect algorithm (Positive Probability Ltd.) installed in LabSolutions Insight Explore CSD can analyze the mass of each molecule from the mass spectrum in which multi-charged ions are distributed.

Fig. 3 shows the result of multi-charged ion analysis of trastuzumab (molecular weight: approximately 148,000). In the result view, the raw data of the mass spectrum to be analyzed is displayed at the top (Fig. 3-A), and the reconstructed zero charge spectrum obtained as a result is displayed below it (Fig. 3-B). The obtained peaks in the reconstructed zero charge spectrum are listed in the lower left (Fig. 3-C), and the mass spectrum peak information corresponding to the row selected in this list is displayed in the lower right (Fig. 3-D) as a list.

In this result, five peaks were obtained in the reconstructed zero charge spectrum (Fig. 3-B), corresponding to the pattern of peaks in the mass spectrum before analysis (Fig. 3-E, enlarged view of Fig. 3-A). The numbers in blue (Fig. 3-B) indicate the

mass difference between the peaks, which are considered to be the peaks of fucose (average molecular weight: 146) and galactose (average molecular weight: 162).




Table 3 Result of Multi-charged Ion Analysis for Trastuzumab

A: raw mass spectrum before analysis, B: reconstructed zero charge spectrum, C: list of the multivalent ion analysis spectrum, D: list of the mass spectrum peaks corresponding to the row selected in the list (C), E: enlargement of the most abundant peak, indicated with the gray arrow in (A)

## Conclusion

Intact analysis of trastuzumab was performed by the quadrupole time-of-flight mass spectrometer LCMS-9030. The reconstructed zero charge spectrum of glycoform patterns can be detected as a result of multivalent ion analysis by the ReSpect algorithm installed in LabSolutions Insight Explore CSD. This method is applicable for the intact analysis of monoclonal antibodies and antibody drug conjugates.

## Acknowledgments

We are grateful to Dr. Yusuke Masuo (Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan) for generously providing us with the sample.

Nexera and LabSolutions Insight Explore are trademarks of Shimadzu Corporation or its affiliated companies in Japan and/or other countries.



Shimadzu Corporation

www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country. The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. See <http://www.shimadzu.com/about/trademarks/index.html> for details. Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own. The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

01-00474-EN

First Edition: Jun. 2023